Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Superiority Standard? Groups Bristle At CMS’ Transcatheter Valve Trial Proposal

This article was originally published in The Gray Sheet

Executive Summary

Some worry that a provision in CMS’ proposed national coverage decision for transcatheter aortic valve replacement devices, which restricts coverage for off-label indications to trials designed to show superiority, signals the agency’s intent to play a more active role in dictating trial designs.

You may also be interested in...

CMS Sticks To Its Guns: Amyvid Alzheimer’s Screening Not Covered In Medicare Population

The final coverage decision for Lilly’s Amyvid sticks with the proposal to limit payment to use in clinical trials. That is a setback for Lilly, but reinforces the Medicare agency’s commitment to the Coverage with Evidence Development pathway.

Industry Pushes CMS For Details On Centralized Coverage Review Of IDE Trials

Whether they support centralized review or not, device manufacturers want CMS to provide more detail on how the process would work – including timelines, the extent of manufacturer interactions with agency staff, and how appeals would be handled.

CMS Proposes Centralized Review, New Standards For Reimbursement Of IDE Studies

Centralized CMS review for Medicare coverage of device studies, as proposed in the 2014 draft physician fee schedule, could make for a more manageable process. But a provision that IDE trials must be designed to show superiority to be “automatically” covered could face industry pushback.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts